Investors reacted sharply on Thursday as Moderna shares plummeted up to 25 percent following an unauthorized leak of partial data regarding its highly anticipated cancer vaccine. The sudden selloff occurred even though the complete dataset, which was released shortly after the leak, actually outperformed many Wall Street expectations. Developed in partnership with Merck, the personalized treatment known as intismeran autogene aims to revolutionize how doctors approach melanoma.
The clinical findings revealed a significant leap in patient outcomes when the vaccine was paired with Merck’s immunotherapy drug, Keytruda. According to the data, the combination therapy reduced the risk of cancer recurrence or death by 42 percent compared to using Keytruda alone. Furthermore, there was a 38 percent reduction in the risk of cancer spreading to distant organs or resulting in death, marking what many experts consider a major step forward in oncology.
This volatility comes at a time when anticipation for Moderna’s pipeline has reached a fever pitch. The company’s stock had surged over 530 percent so far this year as investors bet on the firm diversifying beyond its famous Covid-19 shots into flu and RSV treatments. While Merck saw a minor dip of about 1 percent during Thursday’s trading session, both companies view this targeted vaccine as a potential blueprint for treating various other types of cancer in the future.
Despite the medical success, some logistical hurdles remain due to the bespoke nature of each dose. Currently, the complex manufacturing process takes roughly six weeks per patient. However, Merck CEO Robert Davis recently indicated that his team is working to streamline production timelines to ensure these life saving therapies can reach patients faster once they hit the market. Full details from the phase three trials are expected to be formally presented at the European Society for Medical Oncology conference this weekend.
